中国病理生理杂志2011，Vol.27Issue(3)：603-606,4.DOI:10.3969/j.issn.1000-4718.2011.03.037
融合蛋白AML1-ETO的生物学功能及致癌机制探讨
Biological function and cancerogenic mechanism of AML1-ETO fusion protein
摘要
Abstract
AML1 - ETO fusion protein is the product of ( 8; 21 ) translocation in M2 type acute myelocytic leukemia ( AML ). As a transcription repressor, AML1 - ETO can block the differentiation of hematopoietic cells by repressing the expression of some important hematopoiesis -related transcription factors. Recent results indicate that the fusion protein also induces the epigenetic silencing of some target genes, resulting in the delay of hematopoietic maturation.Moreover, AML1 -ETO promotes the proliferation of hematopoietic stem cells through up -regulating the expression of Jagged1 and miR - 24. Meanwhile, a panel of results in the pathogenesis of AML1 - ETO show that the expression of AML1 -ETO alone can not induce AML. The secondary events or hits like c - kit gene mutation and the AML1 - ETO9a truncation play an important role in leukemogenesis of AML1 - ETO - positive cells.关键词
AML1-ETO融合蛋白/转录阻遏/造血干细胞/二次打击事件分类
医药卫生引用本文复制引用
刘晓晓,张波,赵倩..融合蛋白AML1-ETO的生物学功能及致癌机制探讨[J].中国病理生理杂志,2011,27(3):603-606,4.基金项目
国家自然科学基金资助项目(No.30870979) （No.30870979）
上海科委基础研究重点资助项目(No.08JC1413500) （No.08JC1413500）
